COMBINATION EFFECT OF FINERENONE AND EMPAGLIFLOZIN IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES USING A UACR ENDPOINT STUDY (CONFIDENCE)—BASELINE CHARACTERISTICS

  Back
COMBINATION EFFECT OF FINERENONE AND EMPAGLIFLOZIN IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES USING A UACR ENDPOINT STUDY (CONFIDENCE)—BASELINE CHARACTERISTICS
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than January 23, 2025. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
 
Rajiv
Agarwal
14
Jennifer B. Green Jennifer.Green@Duke.edu Duke University School of Medicine Division of Endocrinology, Department of Medicine and Duke Clinical Research Institute Durham United States
Hiddo J.L. Heerspink h.j.lambers.heerspink@umcg.nl University Medical Centre Groningen Department of Clinical Pharmacy and Pharmacology Groningen Netherlands
Johannes F.E. Mann prof.j.mann@googlemail.com KfH Kidney Centre Munich and Friedrich Alexander University Department of Nephrology & Hypertension Munchen Germany
Janet B. McGill jmcgill@wustl.edu Washington University in St. Louis Division of Endocrinology, Metabolism & Lipid Research, John T. Milliken Department of Internal Medicine St. Louis United States
Amy K. Mottl amy_mottl@med.unc.edu UNC School of Medicine University of North Carolina Kidney Center Chapel Hill United States
Julio Rosenstock juliorosenstock@dallasdiabetes.com Velocity Clinical Research at Medical City Senior Scientific Advisor Dallas United States
Peter Rossing peter.rossing@regionh.dk Steno Diabetes Center Copenhagen and University of Copenhagen Department of Clinical Medicine Herlev Denmark
Muthiah Vaduganathan mvaduganathan@bwh.harvard.edu Brigham and Women's Hospital and Harvard Medical School Division of Cardiovascular Medicine Boston United States
Meike Brinker meike.brinker@bayer.com Bayer AG Cardiology and Nephrology Clinical Development Wuppertal Germany
Robert Edfors Robert.edfors@ki.se Karolinska Institutet Department of Clinical Sciences, Danderyd University Hospital, Division of Cardiovascular Medicine Stockholm Sweden
Na Li linda.li@bayer.com Bayer Healthcare Global Clinical Leader Beijing China
Markus F. Scheerer markus.scheerer@bayer.com Bayer AG Medical Affairs and Pharmacovigilance Berlin Germany
Charlie Scott charlie.scott@bayer.com Bayer PLC Clinical Statistics and Analytics Reading United Kingdom
Masaomi Nangaku mnangaku@m.u-tokyo.ac.jp The University of Tokyo Graduate School of Medicine Division of Nephrology and Endocrinology Tokyo Japan